ConductScience.org, home

Paper22913596

Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.

Thompson JD and 7 others. Nucleic Acid Ther, 2012. Cited by 69 papers, by iCite.

Cite this record

ConductScience Library. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Papers, record 22913596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22913596

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.
PubMed
Journal
Nucleic Acid Ther
PubMed
Year
2012
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
1.93
iCite
Revised in PubMed
2021-10-21
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Thompson JDJames D
2Kornbrust DJDouglas J
3Foy JWJeffrey W-D
4Solano ECElisabeth C R
5Schneider DJDavid J
6Feinstein EElena
7Molitoris BABruce A
8Erlich SShai

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RNA, MessengerMajor topic
RNA, Small InterferingMajor topic
Tumor Suppressor Protein p53Major topic
Administration, Intravenous
Animals
Area Under Curve
Drug Evaluation, Preclinical
Female
Kidney
Macaca fascicularis
Male
Metabolic Clearance Rate
Rats
Rats, Sprague-Dawley
Renal Insufficiency
Tissue Distribution

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 DK079312NIDDK NIH HHSUnited StatesP30DK079312PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02530359Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney InjuryBackground

Source ClinicalTrials.gov

Download CSV of trials

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110640282Chemically modified oligonucleotides exhibit decreased immune stimulation in mice.J Pharmacol Exp Ther2000https://conductscience.org/library/papers/10640282PubMed
212771196Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.Nucleic Acids Res2003https://conductscience.org/library/papers/12771196PubMed
39236854Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.Anticancer Drug Des1997https://conductscience.org/library/papers/9236854PubMed
416714375Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules.Drug Metab Dispos2006https://conductscience.org/library/papers/16714375PubMed
515665597Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.Oligonucleotides2004https://conductscience.org/library/papers/15665597PubMed
69310342Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.Biochem Pharmacol1997https://conductscience.org/library/papers/9310342PubMed
79351904Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.Drug Metab Dispos1997https://conductscience.org/library/papers/9351904PubMed
819470675siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury.J Am Soc Nephrol2009https://conductscience.org/library/papers/19470675PubMed
94893532Methylated ribonucleic acids.Physiol Rev1969https://conductscience.org/library/papers/4893532PubMed
1010960462Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice.Hepatology2000https://conductscience.org/library/papers/10960462PubMed
1110367666Synthetic oligonucleotides: the development of antisense therapeutics.Toxicol Pathol1999https://conductscience.org/library/papers/10367666PubMed
1211471755Ribozyme pharmacokinetic screening for predicting pharmacodynamic dosing regimens.Curr Issues Mol Biol2000https://conductscience.org/library/papers/11471755PubMed
1310435752Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse.Antisense Nucleic Acid Drug Dev1999https://conductscience.org/library/papers/10435752PubMed
149573607Antisense therapeutics.Biotechnol Genet Eng Rev1998https://conductscience.org/library/papers/9573607PubMed
157929417Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.J Biol Chem1994https://conductscience.org/library/papers/7929417PubMed
1618480187Complement cascade activation after an acute psychological stress task.Psychosom Med2008https://conductscience.org/library/papers/18480187PubMed

Download CSV of references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
41282595siRNA-mediated therapeutic approaches improve acute kidney injury and limit its worsening.Front Pharmacol2025https://conductscience.org/library/papers/41282595PubMed
37892179Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing.Biomolecules2023https://conductscience.org/library/papers/37892179PubMed
37868774Using RNA-based therapies to target the kidney in cardiovascular disease.Front Cardiovasc Med2023https://conductscience.org/library/papers/37868774PubMed
37430086Where should siRNAs go: applicable organs for siRNA drugs.Exp Mol Med2023https://conductscience.org/library/papers/37430086PubMed
36960337Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles.Front Med (Lausanne)2023https://conductscience.org/library/papers/36960337PubMed
35680378RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.J Pharmacol Exp Ther2023https://conductscience.org/library/papers/35680378PubMed
35055900RNAi for Western Corn Rootworm Management: Lessons Learned, Challenges, and Future Directions.Insects2022https://conductscience.org/library/papers/35055900PubMed
34638486Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes.Cancers (Basel)2021https://conductscience.org/library/papers/34638486PubMed
34567044RNA Interference-Based Forest Protection Products (FPPs) Against Wood-Boring Coleopterans: Hope or Hype?Front Plant Sci2021https://conductscience.org/library/papers/34567044PubMed
34277620The Genomic Response to TGF-β1 Dictates Failed Repair and Progression of Fibrotic Disease in the Obstructed Kidney.Front Cell Dev Biol2021https://conductscience.org/library/papers/34277620PubMed
33997814Transient siRNA-mediated protein knockdown in mouse followed by feeding/starving cycle and liver tissue analysis.STAR Protoc2021https://conductscience.org/library/papers/33997814PubMed
33513339The growth of siRNA-based therapeutics: Updated clinical studies.Biochem Pharmacol2021https://conductscience.org/library/papers/33513339PubMed
33376785Kidney-Targeted Cytosolic Delivery of siRNA Using a Small-Sized Mirror DNA Tetrahedron for Enhanced Potency.ACS Cent Sci2020https://conductscience.org/library/papers/33376785PubMed
33043785Large animal models for translational research in acute kidney injury.Ren Fail2020https://conductscience.org/library/papers/33043785PubMed
32893005Paving the Road for RNA Therapeutics.Trends Pharmacol Sci2020https://conductscience.org/library/papers/32893005PubMed
32709999Dendrimer-coated carbon nanotubes deliver dsRNA and increase the efficacy of gene knockdown in the red flour beetle Tribolium castaneum.Sci Rep2020https://conductscience.org/library/papers/32709999PubMed
32670333Biosafety of GM Crop Plants Expressing dsRNA: Data Requirements and EU Regulatory Considerations.Front Plant Sci2020https://conductscience.org/library/papers/32670333PubMed
32561705Therapeutic siRNA: state of the art.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32561705PubMed
32391029Safety Considerations for Humans and Other Vertebrates Regarding Agricultural Uses of Externally Applied RNA Molecules.Front Plant Sci2020https://conductscience.org/library/papers/32391029PubMed
32311310Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo.Nucleic Acid Ther2021https://conductscience.org/library/papers/32311310PubMed

See all 35 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22913596

GET https://conductscience.org/api/papers/v1/22913596/cited_by?page=2